3-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)propan-1-ol | 1051372-06-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)propan-1-ol
• 英文别名: 3-[3-(2-Chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]propan-1-ol；3-[3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]propan-1-ol
• CAS: 1051372-06-5
• 化学式: C₁₁H₁₀ClFN₂O₂
• mdl: MFCD22851256
• 分子量: 256.664
• InChiKey: JDSJJJCCXDEGCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)propan-1-ol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 以84%的产率得到3-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)propanal
  参考文献：
  名称：

  Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2

  摘要：

  Structural modifications to the central portion of the N-arylamide oxadiazole scaffold led to the identification of N-arylpiperidine oxadiazoles as conformationally constrained analogs that offered improved stability and comparable potency and selectivity. The simple, modular scaffold allowed for the use of expeditious and divergent synthetic routes, which provided two-directional SAR in parallel. Several potent and selective agonists from this novel ligand class are described. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.096
• 作为产物：
  描述：

  3-[3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]propanoic acid 在 trimethylsilyldiazomethane 、 二异丁基氢化铝 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以66%的产率得到3-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)propan-1-ol
  参考文献：
  名称：

  Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2

  摘要：

  Structural modifications to the central portion of the N-arylamide oxadiazole scaffold led to the identification of N-arylpiperidine oxadiazoles as conformationally constrained analogs that offered improved stability and comparable potency and selectivity. The simple, modular scaffold allowed for the use of expeditious and divergent synthetic routes, which provided two-directional SAR in parallel. Several potent and selective agonists from this novel ligand class are described. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.096

文献信息

• Discovery and Optimization of a Novel Series of <i>N</i>-Arylamide Oxadiazoles as Potent, Highly Selective and Orally Bioavailable Cannabinoid Receptor 2 (CB₂) Agonists
  作者：Yuan Cheng、Brian K. Albrecht、James Brown、John L. Buchanan、William H. Buckner、Erin F. DiMauro、Renee Emkey、Robert T. Fremeau、Jean-Christophe Harmange、Beth J. Hoffman、Liyue Huang、Ming Huang、Josie Han Lee、Fen-Fen Lin、Matthew W. Martin、Hung Q. Nguyen、Vinod F. Patel、Susan A. Tomlinson、Ryan D. White、Xiaoyang Xia、Stephen A. Hitchcock

  DOI：10.1021/jm800463f

  日期：2008.8.1

  describe the discovery of a novel class of oxadiazole derivatives from which potent and selective CB2 agonist leads were developed. Initial hit 7 was identified from a cannabinoid target-biased library generated by virtual screening of sample collections using a pharmacophore model in combination with a series of physicochemical filters. 7 was demonstrated to be a selective CB2 agonist (CB2 EC50 = 93

  CB2受体是止痛药和抗炎药的有吸引力的治疗靶标。在本文中，我们描述了发现一类新的恶二唑衍生物的发现，由此开发了有效的和选择性的CB2激动剂。通过使用药效团模型结合一系列物理化学过滤器对样品集合进行虚拟筛选，从大麻靶偏倚的文库中识别出最初的第7个匹配项。7被证明是选择性CB2激动剂（CB2 EC50 = 93 nM，Emax = 98％，CB1 EC50> 10 microM）。但是，该化合物在大鼠中表现出较差的溶解性和相对较高的清除率，导致口服生物利用度低。在本文中，我们报告了有关提高功效，理化性质和溶解度的7条途径的详细SAR研究。
• Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2
  作者：Erin F. DiMauro、John L. Buchanan、Alan Cheng、Renee Emkey、Stephen A. Hitchcock、Liyue Huang、Ming Y. Huang、Brett Janosky、Josie H. Lee、Xingwen Li、Matthew W. Martin、Susan A. Tomlinson、Ryan D. White、Xiao Mei Zheng、Vinod F. Patel、Robert T. Fremeau

  DOI：10.1016/j.bmcl.2008.06.096

  日期：2008.8

  Structural modifications to the central portion of the N-arylamide oxadiazole scaffold led to the identification of N-arylpiperidine oxadiazoles as conformationally constrained analogs that offered improved stability and comparable potency and selectivity. The simple, modular scaffold allowed for the use of expeditious and divergent synthetic routes, which provided two-directional SAR in parallel. Several potent and selective agonists from this novel ligand class are described. (c) 2008 Elsevier Ltd. All rights reserved.